The estimated Net Worth of Christopher R. Loose is at least $7.53 Milión dollars as of 27 July 2023. Mr. Loose owns over 2,717 units of Frequency Therapeutics Inc stock worth over $55,095 and over the last 5 years he sold FREQ stock worth over $4,581,632. In addition, he makes $2,894,520 as Co-Founder a Chief Scientific Officer at Frequency Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Loose FREQ stock SEC Form 4 insiders trading
Christopher has made over 33 trades of the Frequency Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,717 units of FREQ stock worth $1,359 on 27 July 2023.
The largest trade he's ever made was selling 24,000 units of Frequency Therapeutics Inc stock on 14 December 2020 worth over $889,680. On average, Christopher trades about 6,017 units every 29 days since 2019. As of 27 July 2023 he still owns at least 183,650 units of Frequency Therapeutics Inc stock.
You can see the complete history of Mr. Loose stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Loose biography
Dr. Christopher R. Loose Ph.D. serves as Co-Founder, Chief Scientific Officer of the Company. Prior to our Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Since 2014, Dr. Loose has served as an Associate Professor Adjunct of Urology at the Yale School of Medicine. Dr. Loose is also the Executive Director of Yale University’s Center for Biomedical and Interventional Technology. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.
What is the salary of Christopher Loose?
As the Co-Founder a Chief Scientific Officer of Frequency Therapeutics Inc, the total compensation of Christopher Loose at Frequency Therapeutics Inc is $2,894,520. There are 1 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
How old is Christopher Loose?
Christopher Loose is 39, he's been the Co-Founder a Chief Scientific Officer of Frequency Therapeutics Inc since 2016. There are 17 older and no younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
What's Christopher Loose's mailing address?
Christopher's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Insiders trading at Frequency Therapeutics Inc
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer a Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
What does Frequency Therapeutics Inc do?
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
What does Frequency Therapeutics Inc's logo look like?
Complete history of Mr. Loose stock trades at Frequency Therapeutics Inc
Frequency Therapeutics Inc executives and stock owners
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Lucchino,
President, Chief Executive Officer, Co-Founder, Director -
Christopher Loose,
Co-Founder, Chief Scientific Officer -
Carl LeBel,
Chief Development Officer -
David L. Lucchino,
Co-Founder, Pres, CEO & Director -
Wendy S. Arnold,
Chief People Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Robert Langer,
Independent Director -
Marc Cohen,
Lead Independent Chairman of the Board Director -
Joel Marcus,
Independent Director -
Michael Huang,
Independent Director -
Timothy Barberich,
Independent Director -
Carlo Tanzi,
IR Contact Officer -
Cynthia Feldmann,
Independent Director -
Dana Hilt,
Chief Medical Officer -
Ajay Rai,
Vice President - Business Development -
Richard Mitrano,
Vice President of Finance and Operations -
Wendy Arnold,
Chief People Officer -
William Mclean,
Co-Founder, Vice President - Biology and Regenerative Medicine -
Dr. Carl P. LeBel,
Chief Devel. Officer -
Dr. Christopher R. Loose,
CoÂ-Founder & Chief Scientific Officer -
Dr. William W. Chin M.D.,
Sr. VP of Translational Medicine -
Dr. Dana C. Hilt,
Chief Medical Officer -
Dr. Jeff Hrkach,
Sr. VP of Technology Devel. -
Richard J. Mitrano,
VP of Fin. & Operations -
William J. McLean Ph.D.,
Co-founder & Sr. VP of Hearing Biology and Translational Research -
Quentin Mc Cubbin,
Chief Manufacturing Officer -
James E Deerfield Mgmt L.P....,
-
Peter P. Pfreundschuh,
Chief Financial Officer -
Michael Bookman,
General Counsel and Secretary